医学
间充质干细胞
冠状病毒
免疫系统
临床试验
炎症
免疫学
2019年冠状病毒病(COVID-19)
疾病
免疫
干细胞
干细胞疗法
重症监护医学
传染病(医学专业)
病理
生物
遗传学
作者
Ya-Chao Tao,En‐Qiang Chen
出处
期刊:Current stem cell research & therapy
[Bentham Science]
日期:2024-01-01
卷期号:19 (1): 55-62
被引量:1
标识
DOI:10.2174/1574888x18666230118122256
摘要
The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a serious challenge for human health. In severe cases, patients suffer from acute respiratory distress syndrome even organ failure, usually owing to the dysregulated immune response and widespread inflammation. Considering that there is no known cure for COVID-19 despite the increased morbidity and mortality rate of COVID-19, modalities targeting immunity and inflammation may be promising therapeutics against COVID-19. Mesenchymal stem cells (MSCs) possessing immunomodulatory, anti-inflammatory, anti-apoptotic, and antiviral properties, can be of potential benefit to a subset of severe and critically ill patients with COVID-19. In the present study, we described the underlying mechanisms of MSCs therapy and provided a thorough research study on the recent clinical trials of MSCs for SARS-CoV-2 infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI